HSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings rebound
Investing.com -- HSBC upgraded Dr Reddy’s Laboratories to Buy from Hold and raised its target price to INR 1445, citing expectations that sales of semaglutide, a generic version of Novo Nordisk’s blockbuster weight-loss and diabetes drug, will help drive a recovery in earnings growth from fiscal 2027.HSBC’s new target for the U.S.-listed ADR is $16.90, up from $14.44.